Answers are grounded in this paper and cite their sources.
Acute heart failure is a challenging and sometimes life-threatening condition in acute cardiovascular care. It is the most common cause for hospitalization of patients older than 65 years in developed countries and its prevalence is expected to increase further. Therefore, we felt it important to dedicate an entire issue to the diagnosis and management of acute heart failure. Acute dyspnea, severe enough to activate the emergency medical system constitutes a major diagnostic challenge to the prehospital medical team as this symptom can be the clinical presentation of very different cardiac and pulmonary conditions. Moreover, heart and lung diseases coexist in many patients what further complicates the differential diagnosis. Any diagnostic uncertainty and subsequent delay in treatment may possibly result in more complications, a slower recovery and a prolonged hospitalization if not an increased mortality in acutely dyspneic patients. The 2016 European Society of Cardiology (ESC) guidelines for the diagnosis and treatment of acute and chronic heart failure recommend to measure natriuretic peptides in all patients with acute dyspnea and suspected acute heart failure in order to help in the differentiation of acute heart failure from non-cardiac causes of acute dyspnea.1 In this issue the results are reported from a randomized controlled trial performed in Denmark that examined if routine point of care (POC) measurement of N-terminal pro-brain natriuretic peptide (NT-proBNP) improves the diagnostic work-up by the prehospital critical care team physician in patients with severe dyspnea with suspicion on acute heart failure.2 The routine addition of prehospital NT-proBNP measurement did not improve the triage of the patients directly to the department of cardiology and did not significantly improve treatment or patient outcomes. This negative study result could in part be explained by the presence in the study population of a high proportion of dyspneic patients with pneumonia and sepsis and possibly also by insufficient experience on the use of the NT-proBNP measurement for guiding prehospital therapies. Further studies should therefore focus on strategies not only to perfect the pre-hospital diagnosis -possibly by adding biomarkers of infection- but also to improve the overall prehospital management of acute dyspneic patients by using earlier and more tailored biomarker guided therapies. Lung ultrasound examination has been proposed as a new standard for the diagnosis and monitoring of pulmonary congestion in patients with acute heart failure3,4 that easily can be combined with a focused ultrasound examination of the heart and the vena cava.5 The application of these ultrasound techniques integrated with bedside physical examination and biomarker measurement allows a more dynamic monitoring of the early treatment of patients with acute heart failure. In a small prospective study in patients with acute heart failure these techniques were performed both on admission to the emergency department and serially during the initial treatment in order to assess which test/parameter best predicts complete resolution of pulmonary congestion at hospital discharge.6 A rapid (<12 hours) decline of E/E’ (ratio of mitral inflow early diastolic E wave to medially derived early diastolic tissue Doppler E’ wave) was the strongest predictor of pulmonary congestion resolution on discharge and was the sole predictor for 6-month survival regarding all-cause mortality and the composite endpoint of all-cause mortality or rehospitalization. It appears therefore useful in acute heart failure patients to monitor the early treatment response within 12 hours by measuring the E/E’ parameter. Bedside echocardiography may also be useful for monitoring the hemodynamic response to inotropic therapy in acute heart failure. In a small feasibility study the peak systolic velocity of the mitral annulus (S′) by tissue Doppler imaging (TDI) was more feasible than global longitudinal strain and strain rate derived by speckle tracking echocardiography and performed better than the established wall motion score index.7 S′ by TDI is therefore the preferred echocardiographic parameter for the assessment of changes in left ventricular systolic function during inotropic therapy in patients with acute heart failure. Venous congestion due to intravascular fluid redistribution and/or overload is the dominant hemodynamic pattern responsible for the development of acute heart failure symptoms. It also has become clear that congestion related organ injury contributes to heart failure progression8,9 in a downward spiral of serial episodes of acutely decompensated heart failure. Clinical evaluation of intravascular volume overload is not very accurate, but recently a method for estimation of the plasma volume status based on simple calculation from weight and hematocrit has been validated in chronic heart failure patients.10 Plasma volume status calculated with this simple method was an independent predictor of long term outcome in large retrospective series of patients hospitalized with acute heart failure.11 Development of new-onset heart failure after acute myocardial infarction is influenced by the extent of myocardial injury and by the process of left ventricular recovery and remodeling. Cardiac magnetic resonance imaging (cMRI) performed in large study group of acute myocardial infarction patients included in the Intracoronary Abciximab and Aspiration Thrombectomy in Patients with Large Anterior Myocardial Infarction (INFUSE-AMI) trial showed that cMRI derived infarct size, ejection fraction and left ventricular remodeling parameters were independent determinants of 30-day heart failure12 Although these results are rather confirmatory, the study clearly demonstrates the utility of cMRI in the post-infarction risk stratification of patients with large anterior wall infarctions. Prolonged activation of the innate immune system has been implicated in the pathogenesis and progression of chronic heart failure. It remains however unknown whether activation of the innate immunity also plays a role in triggering acute heart failure syndromes. The possible role of the activation of innate immunity in the pathogenesis of acute heart failure was assessed in a prospective study by measuring levels of complement activation products in the peripheral blood of patients admitted with acute heart failure13 It was found that acute heart failure patients showed increased plasma levels of the complement activation proteins. Complement protein levels were significantly higher in individuals with an infectious cause triggering the acute heart failure syndrome. These findings suggest that activation of innate immune pathways may possibly trigger acute heart failure syndromes at least in some patients (with infections?). The mechanisms involved in complement activation, the consequences of complement activation on the failing heart and the potential clinical implications of innate immune activation in acute heart failure patients are discussed in an accompanying editorial.14 Further evidence for a role of inflammation in the pathogenesis of acute heart failure comes from a large registry that assessed the prognostic impact of pneumonia and signs of systemic inflammation in patients with acute heart failure.15 In this registry pneumonia was relatively common but inflammation in general seemed more important than pneumonia itself for long-term prognosis as only C-reactive protein was an independent predictor for long-term mortality. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is increasingly used as a short-term circulatory support in patients with refractory cardiogenic shock, providing a bridge to long-term mechanical circulatory support or heart transplantation. A report on the successful transfer of cardiogenic shock patients using an air lift demonstrates the feasibility of very long-distance medical evacuation of cardiogenic shock patients on VA-ECMO for emergency heart transplantation, with acceptable long-term results.16 At the end of this issue an educational review paper is published on the diagnosis and management of diuretic resistance in acute heart failure.17
No takes yet. Share an insight, caveat, or question.
Christiaan Vrints (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: